Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Oct 21, 2009

News Details

Corporate | 21 October 2009 15:50

Eckert & Ziegler commissioned to produce an innovative cancer medication

Eckert & Ziegler Strahlen- und Medizintechnik AG / Contract

21.10.2009

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 21 October 2009 - Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700) today announced that it has been commissioned to
produce an innovative cancer medication for the American drug developer
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) based in Cambridge, MA.
Eckert & Ziegler will set up a new production plant for this purpose at its
Braunschweig location with financial support from MIPI. The compound
Onalta(R), is a novel radiotherapeutic product candidate under development
for the treatment of certain neuroendocrine tumors. The delivery peptide
will be combined with a therapeutic radioisotope (90Y edotreotide) at the
plant to produce the drug product. The production plant will be used for
both the manufacture of test batches for clinical development and, later,
for the manufacture of the approved radiopharmaceuticals.

The Eckert & Ziegler Executive Board member with responsibility for the
Radiopharmaceuticals segment, Dr. André Hess, had this to say: 'We are very
pleased to have been selected by MIPI as a strategic partner for this
interesting and, from a medical point of view, extremely important product.
This decision shows that the Radiopharmaceuticals division we launched just
a few years ago, an approved manufacturer of pharmaceuticals, has both the
skills in radiochemical technology and the infrastructure required to
satisfy the needs of innovative R&D companies such as MIPI. We expect many
more projects of this kind in the years to come, and are confident that we
will be able to build on our position as one the world's most important
provider of nuclear-imaging compounds.' Eckert & Ziegler already has a
number of radiopharmaceutical production locations in Germany and markets
the approved product Yttriga(R), a preliminary stage for many radiotherapy
treatments, as well as fluorine-18-based radiodiagnostic compounds for
nuclear imaging (PET). In addition, Eckert & Ziegler supplies
nuclear-imaging facilities around the world with synthesis technology and
gallium-68 radionuclide generators.

Molecular Insight's President and CEO, Daniel L. Peters, said: 'This
agreement is the basis for the supply of the pivotal studies and the
subsequent manufacture of the approved product. Onalta(R) is a novel
radiotherapeutic product candidate for treatment of inoperable
neuroendocrine tumors. This collaboration is the first step in Molecular
Insight's strategy to advance the Company's broad pipeline of five clinical
candidates through collaboration with strategic partners and through the
Company's own development efforts.'

About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG
ist a holding company whose specialized subsidiaries are engaged worldwide
in the processing of radioistoopes and the development, manufacture and
sale of components based on isotope technology, radiation equipment and
radio-pharmaceuticals or of related products. Eckert & Ziegler AG is one of
the world's largest providers of isotope component technology for radiation
therapy and nuclear medicine and is listed at the Frankfurt stock exchange.
The Berlin based company has 520 employees and expects sales of approx. 100
Mio EUR in 2009. For more information see www.ezag.com

About Molecular Insight Pharmaceuticals, Inc.: Molecular Insight
Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer
in the emerging field of molecular medicine. The company is focused on the
discovery and development of therapeutic radiopharmaceuticals and targeted
molecular imaging in oncology and cardiology. Molecular Insight has five
clinical-stage candidates in development. In addition to Onalta(R), the
Company's other oncology candidates include Azedra(TM), currently in a
pivotal trial for pheochromocytoma, Solazed(TM) for treatment of malignant
metastatic melanoma, and Trofex(TM)for detecting metastatic prostate
cancer. Zemiva(TM) is being developed for the diagnosis of acute myocardial
ischemia. For more information on Molecular Insight Pharmaceuticals, please
visit www.molecularinsight.com.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations & PR,
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 941084-138, Fax-112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de

21.10.2009 Financial News transmitted by DGAP

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg

End of News DGAP News-Service

---